Breast Cancer

Gabriel N. Hortobagyi, MD, MACP, FASCO, a professor at the University of Texas MD Anderson Cancer Center, discussed the final data on invasive disease-free survival from the NATALEE trial of ribociclib in combination with a nonsteroid aromatase inhibitor (NSAI).

Mara Hofherr, PharmD, a clinical oncology pharmacist at Washington University, highlights key findings of the KEYNOTE-522 trial in comparison of outcomes between Black and White patients with triple-negative breast cancer.

Gabriel Hortobagyi, MD, FACP, professor and chair emeritus of the Department of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center discusses the changes in breast cancer management over the past decade.

Amelie G. Ramirez, DrPH, MPH, director of the Institute for Health Promotion Research at UT Health Science Center San Antonio, discussed the need for standardized questionnaires for clinicians to discuss social determinants of health with their oncology patients.

The discussion delves into the results and implications of the clinical trials, shedding light on the efficacy and safety profile of this combination therapy.

Individuals with HR+ breast cancer could pause endocrine therapy for up to 2 years to become pregnant, without increasing the risk of recurrence.

Carly Giavatto, PharmD, discusses the CPS conducted study that highlights a first of its kind linkage to care initiative performed by health systems specialty pharmacists.

The investigational combination also delayed the median time to first chemotherapy in all age groups.

Patients with breast cancer who underwent chemotherapy and skipped RNI did not face an increased risk of disease recurrence or death 5 years post-surgery.

Mridula George discusses the role of personalized circulating tumor DNA monitoring in predicting the response to neoadjuvant therapy for early-stage breast cancer.

Trastuzumab deruxtecan and elacestrant both represent important new treatment options for subgroups of patients with breast cancer.

In the first-line setting, inavolisib plus palbociclib and fulvestrant improved PFS in patients with HR-positive breast cancers; however, further research is needed to understand the trends in OS.

Pharmacy Times will be covering the 2023 San Antonio Breast Cancer Symposium (SABCS), happening December 5 through 9 in Texas.

Further research is necessary to better understand the development and factors that contribute to CBC after PBC treatment.

In addition to predicting breast cancer outcomes, the AI tool can help determine effective treatment options in patients, sparing them from unnecessary treatments.

The investigators note that continued support during breast cancer treatment is necessary for patient comfort beyond diagnosis and the initial phases of treatment.

TcdBFBD, derived from a toxin found in Clostridium difficile, was tested in mouse models that mimicked different subtypes of breast cancer.

The study findings indicate that health care professionals significantly underreport symptoms compared to patients with breast cancer, with reported comorbidities varying.

Capivasertib is indicated for hormone receptor-positive, human epidermal growth factor 2-negative locally advanced or metastatic breast cancer with 1 or more PIK3CA/ALT1/PTEN-alterations.

Dr Kettle provide insights into unmet needs surrounding treatment of metastatic breast cancer.

Drs DiMarco and Moore weigh the benefits and barriers associated with clinical pathways in treating patients with mBC.

Medical experts weigh in on key points of emphasis surrounding medication therapy management for patients diagnosed with mBC

Researchers determined that simultaneously targeting the BRD4 and LOXL2 proteins disrupts their interaction and inhibits the growth of triple-negative breast cancer cells.

Dr Kettle outlines NCCN guideline-directed therapy surrounding CDK4/6 inhibitors.

Adverse event profiles of several approved CDK4/6 inhibitors are discussed.

Compared to endocrine therapy alone, the combination of ribociclib and endocrine therapy lowered the risk of cancer recurrence in patients with early breast cancer by 25.2%.

Jacob Kettle, PharmD, BCOP, joins Drs Haumschild and DiMarco in a conversation surrounding findings from the SONIA trial and their impact on shifting mBC treatment strategies.

Expert panelists discuss the impact of CDK4/6 inhibitor therapy on progression-free and overall survival.

This finding underlines the need for methods that address multiple genomic alterations and targeted therapies effective in tumors driven by variations in suppressor genes or transcription factors.